Publikation
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Wissenschaftlicher Artikel/Review - 01.02.2005
Borner M M, Roth A D, Lanz D, Brauchli P, Honegger H, Köberle Dieter, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland